




PHARMACEUTICAL 2023

Aclaris Therapeutics Inc.
Rank 140 of 446





PHARMACEUTICAL 2023

Aclaris Therapeutics Inc.
Rank 140 of 446



The relative strengths and weaknesses of Aclaris Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aclaris Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 60% points. The greatest weakness of Aclaris Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 162%, being 119% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	231,550
Cost of Goods Sold	4,023
Intangible Assets	6,973
Liabilities, Current	21,938
Liabilities, Non-Current	1,570
Other Assets	14,974
Other Compr. Net Income	-673
Other Expenses	12,637
Other Liabilities	33,467
Other Net Income	2,946
Other Revenues	29,752
Property and Equipment	1,099
Research and Development	77,813
Selling, General and Administrative Expense	25,133

Output Variable	Value in 1000 USD
Assets	254,596
Liabilities	56,975
Expenses	119,606
Revenues	29,752
Stockholders Equity	197,621
Net Income	-86,908
Comprehensive Net Income	-87,244
Economic Capital Ratio	162%